Table 1.
Baseline characteristics.
| Baseline Characteristics | |
|---|---|
| Age, median (range) | 58 years (30-85) |
| 18-49 years (%) | 6 (21%) |
| 50-69 years (%) | 20 (69%) |
| ≥70 years (%) | 3 (10%) |
| Sex | |
| Male (%) | 14 (48%) |
| Female (%) | 15 (52%) |
| Race | |
| White (%) | 21 (72.4%) |
| Other/Unknown (%) | 8 (27.6%) |
| Prior systemic treatments, median (range) | 1 (0-5) |
| 0 | 9 (31%) |
| 1 | 7 (24%) |
| ≥2 | 9 (31%) |
| Prior immune checkpoint blockade | 19 (66%) |
| LDH. median (range) | 321 (163-1028) |
| Normal (%) | 13 (45%) |
| Elevated (%) | 14 (48%) |
| >2x Normal (%) | 3 (10%) |
| Unknown (%) | 2 (7%) |
| GNAQ/GNA11 mutation status | |
| GNAQ (%) | 13 (45%) |
| GNA11 (%) | 6 (21%) |
| Unknown (%) | 10 (34%) |
| Sites of metastases | |
| Hepatic only (%) | 4 (14%) |
| Extra-hepatic only (%) | 3 (10%) |
| Hepatic and extra-hepatic (%) | 22 (76%) |
| Uveal Melanoma AJCC M Staging | |
| M1a (%) | 17 (59%) |
| M1b (%) | 9 (31%) |
| M1c (%) | 3 (10%) |